CARDURA
What it isAlpha-1 antagonist; benign prostatic hyperplasia and resistant hypertension.
Why this oneWorse heart-failure outcomes than chlorthalidone ended its first-line hypertension role; BPH is now the more defensible use.
What limits itFirst-dose orthostatic hypotension — start at night. Nonuroselective blockade causes more hypotension than tamsulosin.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Benign prostatic hyperplasia | Adults | 1 mg QD | 2–8 mg QD | 8 mg QD |
| Hypertension | Adults | 1 mg QD | titrate to effect | 16 mg QD |
Titration BPH: increase at 1–2 week intervals.
Renal Undefined
Hepatic Not recommended in severe (Child-Pugh C); monitor BP/hypotension in mild–moderate (A/B)
Pregnancy Limited data insufficient to assess risk; untreated hypertension carries maternal risk
Lactation Undefined
NO BOXED WARNINGS
Principal riskFirst-dose orthostatic hypotension
Cost, est. cash$5–$150/month
Generic entry2000
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

Open Doxazosin in the interactive console ↗

